Protocol 55-1009-1:A Multicenter, Randomized, Double-Blind, Placebo-Controlled, Parallel Group Study to Evaluate the Efficacy, Safety, and Tolerability of Ixmyelocel-T in Subjects With Critical Limb Ischemia and No Options for Revascularization